LWBK1006-43 LWW-Govindan-Review December 14, 2011 15:38
544 DeVita, Hellman, and Rosenberg’s CANCER: Principles and Practice of Oncology Review
Question 43.22. Patients receiving alemtuzumab may experience all of the following
EXCEPT:
A. Increased risk forP. jiroveciinfection
B. Low risk of neutropenia
C. Herpes virus prophylaxis is recommended
D. Treatment results in prolonged lymphopenia
Question 43.23. A 56-year-old man was recently diagnosed with AML and received 7+ 3
induction. Ten days after treatment patient developed neutropenic fever
requiring treatment with broad-spectrum antibiotics. However, his fever
persisted after count recovery. Blood and urine cultures were negative and
the alkaline phosphatase was elevated. CT scan of the abdomen revealed
multiple discrete “bulls eye” lesions on the liver and spleen. What is the
likely cause for the patient’s fever?
A. Candida
B. Escherichia coli
C. Streptococcus
D. Pneumocystis
Question 43.24. Which of the following oral antibiotics has activity against pseudomonas
species?
A. Amoxicillin/clavulanate
B. Cefdinir
C. Clindamycin
D. Levofloxacin
Question 43.25. A 23-year-old man was recently diagnosed with AML and underwent
7 +3 induction. However, he did not recover his counts event after
4 weeks after induction. A workup revealed parvovirus B19 infection.
What is the treatment of choice?
A. Intravenous immunoglobulin
B. Ribavirin
C. Foscarnet
D. Ganciclovir